DOCSLIB.ORG

February 2021 Volume 11 Issue 2 © Copyright 2021 Oregon State University

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
February 2021 Volume 11 Issue 2 © Copyright 2021 Oregon State University THE OREGON STATE DRUG REVIEW© AN EVIDENCE BASED DRUG THERAPY RESOURCE http://pharmacy.oregonstate.edu/drug-policy/newsletter February 2021 Volume 11 Issue 2 © Copyright 2021 Oregon State University. All Rights Reserved Antidepressant Review Kathy Sentena, Pharm.D., Oregon State University Drug Use Research and Management Group Depression is the second leading cause of disability in the Antidepressant Adverse Events United States (US), following cardiovascular disease, and the Minimizing adverse events can increase adherence and leading cause of disability worldwide.1 There have been many treatment success of antidepressant therapy. Common recent challenges which has resulted in rising incidences of antidepressant adverse reactions are sexual dysfunction, depression. Examples of these include Coronavirus Disease- anticholinergic effects, drowsiness, insomnia/agitation, 2019 (COVID-19), loss of employer-provided health insurance, orthostatic hypotension, QTc prolongation, gastrointestinal the opioid pandemic, job termination and isolation. The Centers adverse reactions and weight gain.8 Antidepressants with a for Disease Control and Prevention (CDC) has reported moderate to high risk of certain adverse reactions are increases in mental health challenges, with 40% of adults in the presented in Table 1. Antidepressants in Table 2 are US reporting issues with mental health or substance abuse.2 associated with less risk of common adverse reactions to Depressive disorders were approximately four times higher in help providers select the most appropriate therapy. Boxed April-June of 2020 compared to the same time period in 2019.2 warnings are part of the prescribing information for all Populations that have seen the largest increase in depressive antidepressants due to the risk of suicidal thoughts and disorders are younger adults, racial/ethnic minorities, essential behaviors in pediatric and young adult populations and workers and unpaid adult caregivers. The most recent report therefore, these populations should be monitored more from the CDC on state specific rates found Oregon to be ranked closely. the highest in the country in depression rates.3 In Medicaid patients served by the Oregon Health Plan (OHP) there were over 133,000 patients with antidepressant claims in the second Table 1. Antidepressants Associated with Moderate to High quarter of 2020.4 Persons with mental health disorders are at Levels of Certain Adverse Reactions*8,9 least 10 times as likely to commit suicide or have a suicide Antidepressant Adverse Reaction Level of Risk attempt, emphasizing the importance of appropriate Citalopram QTc Prolongation Moderate managment.5 The combination of non-pharmacologic strategies, Citalopram Sexual High like behavioral counseling, with antidepressants can be Dysfunction Escitalopram Sexual Moderate important tools in optimizing patient care. This newsletter will Fluoxetine Dysfunction focus on initiating, tapering, and switching antidepressants with Paroxetine a brief update on the use of esketamine. Sertraline Mirtazapine Drowsiness High Antidepressants Mirtazapine Weight gain High Providers are familiar with the classes of antidepressants that Venlafaxine Sexual Moderate are available, which include: selective serotonin reuptake Dysfunction inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors Trazodone Drowsiness High (SNRIs), atypical agents (bupropion and mirtazapine), serotonin Trazodone Orthostatic Moderate modulators, tricyclic antidepressants and monoamine oxidase Hypotension inhibitors (MAOIs). Classes of antidepressants are differentiated Trazodone GI adverse Moderate by their mechanisms of action, which corresponds to differing reactions adverse event profiles. Food and Drug Administration (FDA) Vilazodone GI adverse High indications for antidepressants include depression, anxiety reactions Vortioxetine GI adverse Moderate disorders and pain conditions. The National Institute for Health reactions and Care Excellence (NICE) and American Psychiatric Key: * Other antidepressants may be associated with these Association (APA) recommend second-generation adverse reactions but at slight or low risk. antidepressants (SSRIs, SNRIs, or atypical agents) for initial treatment.6,7 There is a lack of evidence from high quality systematic reviews that one second-generation antidepressant is superior to another; therefore, treatment selection should be based on adverse events, patient specific characteristics, tolerability and cost. OREGON STATE DRUG REVIEW Page 2 Table 2. Antidepressant Recommendations for Minimization of Table 3. Key Strategies for Switching Antidepressants10 Certain Adverse Reactions8 Strategies Explanation Recommended Examples Adverse Reaction to Antidepressants with the Least Risk Classes be Avoided Abrupt Stop the initial - SSRI to SSRI+ Citalopram to Sexual Dysfunction Bupropion switch therapy and - SSRI to SNRI sertraline 25 Mirtazapine start the new - SNRI to SSRI mg/day Duloxetine one at a low - SNRI to Vortioxetine dose mirtazapine+ Nefazodone Cross- Gradually - SSRI to SSRI+ Sertraline 50 Drowsiness SSRIs tapering* increase the - SSRI to mg daily to SNRIs dose of the mirtazapine mirtazapine 15 Bupropion new therapy - mirtazapine to mg daily while SSRI Vilazodone decreasing the - SNRI to Vortioxetine existing mirtazapine+ Anticholinergic SSRIs^ therapy - Switching to or SNRIs from bupropion Serotonin modulators* Bupropion Taper and Taper high - High dose SSRI Taper Orthostatic Atypical agents† switch dose to new SSRI paroxetine by hypotension SNRIs antidepressant 25% every 4 QTc Prolongation SNRIs to a low dose to 6 weeks to Atypical agents† before starting 10 mg daily Nefazodone new therapy and then start Vilazodone sertraline 25 vortioxetine mg daily Weight gain Bupropion Taper and Gradually - Fluoxetine (4-7 Taper and Fluoxetine switch taper dose, day washout) to stop SNRIs with stop current venlafaxine or fluoxetine. washout medication duloxetine After washout Serotonin modulators* and allow for start Abbreviations: SNRIs – serotonin-norepinephrine reuptake inhibitors; SSRIs – selective serotonin reuptake inhibitors washout venlafaxine Key: * Nefazodone, trazodone, vilazodone, vortioxetine; † Bupropion, 37.5 mg/day mirtazapine; ^ Paroxetine is not recommended if anticholinergic adverse Abbreviations: SNRIs – serotonin-norepinephrine reuptake inhibitors; reactions are to be avoided SSRIs – selective serotonin reuptake inhibitors Key: * Not recommended with fluoxetine, which should be stopped and the new SSRI should be started after a 7-day washout; + Abrupt switch or Switching Antidepressants cross-tapering can be used Antidepressant therapy should be tried for a minimum of 4 weeks after dose optimization to determine success of therapy. When switching or discontinuing antidepressants there is a Remission of depressive symptoms with the use of an initial risk of discontinuation syndrome. Tapering antidepressants antidepressant treatment only occurs in around one-third of over 6-8 weeks is recommended to avoid this syndrome; patients, thus necessitating switching to a different however, it can still occur. Discontinuation syndrome can 10 antidepressant. There is limited evidence to guide changing last up to 2 weeks and is due to the effects of decreasing antidepressants but in general, if two therapies from the same levels of serotonin and down regulation of receptors. class have not been effective, it is recommended to try an Discontinuation syndrome presents as gastrointestinal flu- option from a different class. Suggested guidance for switching like symptoms, irritability, insomnia, dizziness, vivid dreams antidepressants depends on the class, half-life and specific drug and paresthesias.11 The syndrome is most often seen when characteristics (Table 3). Caution is warranted due to lack of switching from a serotonergic antidepressant to a data on switching the following therapies: vortioxetine, nonserotonergic treatment (e.g., switching from venlafaxine 10 vilazodone, desvenlafaxine, or levomilnacipran. or paroxetine to buproprion) and with therapies with a shorter half-life.10 Discontinuation syndromes can be treated by increasing the dose of the serotonergic agent, repeating the taper at a slower rate or switching the patient to an SSRI with a longer half-life.11 Oregon DUR Board Newsletter Produced by OSU COLLEGE of PHARMACY DRUG USE RESEARCH & MANAGEMENT Managing Editor: Kathy Sentena [email protected] OREGON STATE DRUG REVIEW Page 3 Esketamine Figure 1. Comparative Antidepressant Monthly Cost for Esketamine is a non-competitive N-methyl-D-aspartate (NMDA) Select Agents receptor blocker initially approved for treatment-resistant $480 depression.12 Esketamine must be given under the supervision $500 $450 of a provider and is only available through a Risk Evaluation $405 $400 and Mitigation Strategy (REMs) Program. It is indicated for use $350 $288 along with an oral antidepressant. Esketamine is associated $300 with nausea, vomiting, dissociation, sedation, and misuse. $250 Blood pressure should also be monitored as elevations have $200 been seen for up to 4 hours. Esketamine, 56 or 84 mg, is given $150 as a nasal spray twice weekly for the first month and then once $100 weekly or every other week as maintenance therapy.12 The cost $50 $2 $1 $2 for esketamine for a 30-day supply (given once weekly) is $0 $1585.13 Esketamine received an expanded indication for major depressive disorder with suicidality in July of 2020.12 Two, four- * Prices based on
Load more

Recommended publications
  • Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
    pharmaceuticals Article Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review Marcin Siwek 1,*, Adrian Andrzej Chrobak 2 , Aleksandra Gorostowicz 3, Anna Julia Krupa 3 and Dominika Dudek 2 1 Department of Affective Disorders, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland 2 Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland; [email protected] (A.A.C.); [email protected] (D.D.) 3 Department of Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland; [email protected] (A.G.); [email protected] (A.J.K.) * Correspondence: [email protected]; Tel.: +48-12-424-87-00 Abstract: The efficacy of vortioxetine has been proven in many studies, but data concerning dis- continuation symptoms (DS) after vortioxetine withdrawal is scarce. The aim of our study is to systematically evaluate the prevalence, determinants, and clinical features of vortioxetine DS in a retrospective chart review. Data were obtained from medical records of 263 adult patients with depressive disorders who discontinued former vortioxetine treatment. DS were observed in eight (3%) patients after 71–375 days (median 272) of treatment. DS emerged after median three days following vortioxetine withdrawal and lasted for median seven days. The clinical presentation of DS involved: emotional lability (100% of patients), irritability (75%), sudden worsening of mood (75%), nervousness (37.5%), and agitation (37.5%). Median DESS score was four (range of four to six). DS Citation: Siwek, M.; Chrobak, A.A.; were significantly more prevalent after accidental vs.
    [Show full text]
  • MEDICATION GUIDE TRINTELLIX (Trin'-TELL-Ix) (Vortioxetine)
    Page 1 of 4 MEDICATION GUIDE TRINTELLIX (trin’-TELL-ix) (vortioxetine) Tablets What is the most important information I should know about TRINTELLIX? TRINTELLIX can cause serious side effects, including: • Increased risk of suicidal thoughts and actions. TRINTELLIX and other antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. TRINTELLIX is not for use in children. o Depression or other mental illnesses are the most important causes of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? o Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. o Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings or if you develop suicidal thoughts or actions. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, especially if they are new, worse, or worry you: • attempts to commit suicide • acting on dangerous impulses • acting aggressive or violent • new or worse anxiety or panic • thoughts about suicide or dying • new or worse depression attacks • feeling agitated, restless, angry or • an increase in activity or talking • trouble sleeping irritable more than what is normal for you • other unusual changes in behavior or mood What is TRINTELLIX? TRINTELLIX is a prescription medicine used in adults to treat a certain type of depression called Major Depressive Disorder (MDD).
    [Show full text]
  • Medicines Information Bulletin
    Medicines Information Bulletin Vol. 14 No. 2 Vortioxetine (Brintellix) for depression January 2016 DTG decision: Formulary Restricted The Drugs and Therapeutics Group has included vortioxetine on the formulary as a restricted medicine. It should only be used according to the NICE technology appraisal guidance (TA367)1, which recommends vortioxetine as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode. 1 Vortioxetine is as effective as other antidepressants, but may have a better overall safety profile. Vortioxetine has pro- cognitive effects and NICE suggests that it may be a valuable treatment option for people experiencing cognitive dysfunction as part of their depression.1 Clinicians wishing to prescribe vortioxetine must make an entry in the patient’s notes that clearly describes how the restriction criteria are met. What is it? Vortioxetine is thought to work through a combination of two pharmacological modes of action: reuptake inhibition and receptor activity. In vitro studies indicate that vortioxetine is an inhibitor of the serotonin transporter and also a 5-HT3, 5- HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist. In vivo non-clinical studies have demonstrated that vortioxetine modulates neurotransmission in several systems, including predominantly the serotonin but probably also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems.2 Annual treatment cost for comparison How much does it cost? 3 Vortioxetine has a flat based pricing structure – all per year (MIMS ) £ strengths are £27.72 for a 28 day supply. Vortioxetine 10mg OD 361.35 Mirtazapine 30mg OD 17.72 What is the dose? Venlafaxine 112.5mg BD 63.88 o Adults <65 years of age: 10 mg once daily Venlafaxine MR TABLETS 225mg OD 408.80 (starting and maintenance dose), increase to Venlafaxine MR CAPSULES 225mg OD 767.67 20mg OD or reduce to 5mg OD depending on individual patient response.
    [Show full text]
  • A Serious Dermatological Side Effect Due to Vortioxetine: a Case Report
    DOI: 10.14744/DAJPNS.2019.00064 Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2020;33:87-91 CASE REPORT A serious dermatological side effect due to vortioxetine: a case report Burak Okumus1 , Kader Semra Karatas1 , Asli Enzel Koc1 1Recep Tayyip Erdogan University, Faculty of Medicine, Department of Psychiatry, Rize - Turkey ABSTRACT Major depressive disorder is the second-largest healthcare problem worldwide in terms of illness-induced disability, and second-generation antidepressants are the most commonly used treatments in this disorder. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. Some side effects associated with the use of vortioxetine have been reported. Side effects that do not occur in clinical trials can be reported during phase IV studies. In this case report, we present a patient who developed dermatological adverse reactions following vortioxetine use. Keywords: Ecchymosis, skin eruption, vortioxetine INTRODUCTION changes, sexual dysfunctions, and insomnia that can affect compliance with therapy as well as observed Major depressive disorder (MDD) is a fairly common resistance to treatment indicate a need for new condition that may reduce the quality of life (1). While treatment strategies (1,3). A recent antidepressant with the biological foundations of MDD have not yet been different mechanisms of action for this purpose in sufficiently understood, current theories concentrate on clinical use is vortioxetine (1), a multimodal questions related to neuroplasticity, neurotrophin antidepressant with 5-HT carrier inhibitor, 5-HT3, signaling, the role of neuroinflammation, hyperactivity 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B of the hypothalamus-hypophysis-adrenal axis, and most partial agonist, and 5HT1A agonist properties (4).
    [Show full text]
  • Prescriber's Guide to Using 3 New Antidepressants W
    VILAZODONE • LEVOMILNACIPRAN • VORTIOXETINE Prescriber’s guide to using 3 new antidepressants How do they work? What makes them different? And which patients might benefit most from taking them? Ahmed Z. Elmaadawi, MD Narendra Singh, MD ith a prevalence >17%, depression is one of the most common Jagadeesh Reddy, MD, MPH mental disorders in the United States and the second leading Adjunct Clinical Assistant Professors W 1,2 cause of disability worldwide. For decades, primary care and mental Suhayl Joseph Nasr, MD health providers have used selective serotonin reuptake inhibitors (SSRIs) Volunteer Clinical Professor as first-line treatment for depression—yet the remission rate after the first Department of Psychiatry trial of an antidepressant is <30%, and continues to decline after a first Indiana University School of Medicine- antidepressant failure.3 South Bend Campus South Bend, Indiana That is why clinicians continue to seek effective treatments for depres- sion—ones that will provide quick and sustainable remission—and why Disclosures Drs. Elmaadawi, Singh, and Reddy report no financial scientists and pharmaceutical manufacturers have been competing to relationships with any company whose products develop more effective antidepressant medications. are mentioned in this article or with manufacturers of competing products. Dr. Nasr is a member of the In the past 4 years, the FDA has approved 3 antidepressants— speakers’ bureau for Forest Pharmaceuticals and Takeda vilazodone, levomilnacipran, and vortioxetine—with the hope of Pharmaceutical Company Limited and H. Lundbeck A/S. increasing options for patients who suffer from major depression. These 3 antidepressants differ in their mechanisms of action from other available antidepressants, and all have been shown to have acceptable safety and tolerability profiles.
    [Show full text]
  • Effects of Subchronic Administrations of Vortioxetine, Lurasidone, And
    International Journal of Molecular Sciences Article Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor Motohiro Okada * , Ryusuke Matsumoto, Yoshimasa Yamamoto and Kouji Fukuyama Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan; [email protected] (R.M.); [email protected] (Y.Y.); [email protected] (K.F.) * Correspondence: [email protected]; Tel.: +81-59-231-5018 Abstract: The functional suppression of serotonin (5-HT) type 7 receptor (5-HT7R) is forming a basis for scientific discussion in psychopharmacology due to its rapid-acting antidepressant-like action. A novel mood-stabilizing atypical antipsychotic agent, lurasidone, exhibits a unique receptor-binding profile, including a high affinity for 5-HT7R antagonism. A member of a novel class of antidepres- sants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R. However, the effects of chronic administration of lurasidone, vortioxetine, and the selec- Citation: Okada, M.; Matsumoto, R.; tive serotonin reuptake inhibitor (SSRI), escitalopram, on 5-HT7R function remained to be clarified. Yamamoto, Y.; Fukuyama, K. Effects Thus, to explore the mechanisms underlying the clinical effects of vortioxetine, escitalopram, and of Subchronic Administrations of lurasidone, the present study determined the effects of these agents on thalamocortical glutamatergic Vortioxetine, Lurasidone, and transmission, which contributes to emotional/mood perception, using multiprobe microdialysis Escitalopram on Thalamocortical and 5-HT7R expression using capillary immunoblotting.
    [Show full text]
  • Adult Depression
    PEER REVIEWED FEATURE 2 CPD POINTS Adult depression A step-by-step KEY POINTS • A stepwise approach to evidence-based primary guide to mental health care promotes early detection of patients with depression. • Early detection by GPs encourages more timely treatment access to evidence-based treatments, including easily accessed and destigmatising e-mental health JOSEPHINE ANDERSON BA, BMed(Hons), MMed, MHealthLaw, interventions. FRANZCP, Cert Child Adol Psych • Given the overall similarities in efficacy of VERONICA GALVEZ MB BS, MD antidepressants, the most important considerations COLLEEN LOO MB BS(Hons), FRANZCP, MD when initiating pharmacotherapy are tolerability and PHILIP B. MITCHELL AM, FASSA, MB BS, MD, FRANZCP, FRCPsych safety, although some patients uniquely respond to some medicines and not others. A stepwise approach to the early detection and • For patients with difficult-to-treat depression, an management of depression, guided by severity of algorithmic management approach with steps that presentation and treatment response, can ensure include increasing the antidepressant dose, switching timely access to treatment. Evidence-based antidepressants, augmenting with a nonantidepressant treatment and combining antidepressants improves treatments range from e-mental health apps, the chance of patient recovery. psychological therapy and medication to • Neurostimulatory treatments such as electroconvulsive neurostimulation. therapy and repetitive transcranial magnetic stimulation have an expanding role in the evidence-based treatment of severe depression. ajor depressive disorder occurs in 5% of adults annually and has effects on quality of life equal to or greater than those of ischaemic heart disease or diabetes.1 MedicineToday 2015; 16(11): 16-24 Around 25% of patients who present to their GPs with Amended November 2015 Mdepressive symptoms have major depressive disorder.
    [Show full text]
  • Vortioxetine: a Comprehensive Update on a New- Generation Antidepressant
    DOI: 10.14744/DAJPNS.2021.00115 Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2021;34:1-13 EDITORIAL Vortioxetine: a comprehensive update on a new- generation antidepressant Cuneyt Evren1 1Bakirkoy Training and Research Hospital for Psychiatry Neurology and Neurosurgery, Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Istanbul - Turkey Major depressive disorder (MDD) is a chronic of depressive patients had a sufficient response to a disease defined by one or more major depressive single antidepressant (8) and that remission was lower episodes lasting at least two weeks and no history of in patients with two failed treatments (9). Approximately manic episodes (1). MDD affects approximately 6% of half of patients respond poorly to first-line the world’s adult population each year and is about antidepressant treatment (10). Moreover, current twice as common in women than men (2). This disorder treatments often have side effects (11). A recent increases suicide and some important medical illnesses systematic review and meta-analysis investigated the such as diabetes (3). According to the World Health efficacy and safety of pharmacological and non- Organization (WHO), depressive disorders are the pharmacological treatments for MDD (12). According single largest contributor to non-fatal health loss (7.5% to the results, with the exception of probiotics, all of the of Years Lived with Disability) (4). treatments studied (acupuncture, mirtazapine, herbal Although psychotherapy and electroconvulsive medicine, venlafaxine, physical exercise, cognitive- therapy are used, pharmacotherapy is still typically a behavioral therapy, bupropion, fluoxetine, and primary form of treatment for MDD (5). Tricyclic vortioxetine) appeared to be significantly more effective antidepressants (TSA) and monoamine oxidase than placebo.
    [Show full text]
  • Treatment of Resistant Depression
    Mountain West AIDS Education and Training Center Treatment of Resistant Depression Christine Yuodelis-Flores, MD Aug 25, 2016 This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient. Initial Antidepressant Selection • Selection of antidepressant is based on: - Anticipated side effects and safety/tolerability for the patient. - Pharmacological properties of the medication (T1/2, P450 enzymes, other drug interactions). - Additional factors: medication response in prior episodes, cost, & patient preference • For most patients, start with a selective serotonin reuptake inhibitor (SSRI), mirtazapine, bupropion or serotonin norepinephrine reuptake inhibitor (SNRI). *American Psychiatric Association (APA), Practice Guideline for the Treatment of Patients w/ Major Depressive Disorder, 5/2010) Remission of Major Depressive Episode (MDE)* • 4–8 weeks of treatment at a therapeutic dose are needed before concluding that a patient is partially responsive or unresponsive to a specific medication. • Remission: ≥3 weeks of the absence of both sad mood & reduced interest and no more than 3 remaining sx of MDE. • Patients often have substantial but incomplete sx reduction or improvement in functioning during acute phase treatment. American Psychiatric Assoc., Practice Guideline for the Treatment of Patients w/ Major Depressive Disorder, 5/2010) Treatment Resistant vs Treatment Refractory • Treatment Resistant Depression: Major Depressive Episode (MDE) that does not respond to at least two trials of antidepressant monotherapy. • Treatment Refractory: MDE that does not respond satisfactorily to numerous sequential treatment regimens. *American Psychiatric Assoc., Practice Guideline for the Treatment of Patients w/ Major Depressive Disorder, 5/2010) Residual Depression • Even mild residual symptoms at the end of a MDE are associated with: - Significant psychosocial disability, compared with asymptomatic remission.
    [Show full text]
  • Antidepressant Medications: U.S. Food and Drug Administration
    Antidepressant Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for antidepressant medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved indications and dosages for the use of antidepressant medications in adults are provided in this table. Some of the antidepressant medications are FDA-approved for the treatment of or as adjunct therapy for Parkinson’s disease. This indication is not discussed in this document because of its very specific focus and individualized treatment regimens. All of the antidepressant medications listed are for oral administration unless otherwise stated. Information on the generic availability of antidepressant medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Initial Dose Maximum Dose Other Information Availability amitriptyline[1] depression Outpatients: Outpatients: Outpatients may be initiated at 50 mg Yes 75 mg per day; 150 mg per day; to 100 mg once a day at bedtime. Dose Hospitalized patients: Hospitalized patients: increases should be made gradually by 100 mg per day 300 mg per day 25 mg to 50 mg as necessary, preferably in the late afternoon or evening. Lower doses are recommended for elderly patients. Take in divided doses. amoxapine[2] depression 50 mg 2 or 3 times a day 400 mg per day; May increase dose to 100 mg 2 to 3 times Yes Hospitalized patients a day by the end of the first week.
    [Show full text]
  • NHS Greater Glasgow & Clyde Mental Health Services Antidepressant
    NHS Greater Glasgow & Clyde Mental Health Services Antidepressant switching and stopping General guidance- stopping1 All antidepressants can cause discontinuation symptoms with the possible exceptions of agomelatine and vortioxetine. Abrupt withdrawal should be avoided unless a serious adverse event has occurred. Reduce dose gradually over 4 weeks (except fluoxetine due to its long half-life), this is particularly important in drugs with a short half-life (e.g. paroxetine and venlafaxine). Discontinuation symptoms (these can be drug specific, consult individual SPC for further information) include: • Agitation • Flu-like symptoms • Headache • Insomnia • Irritability • Shock-like sensations • Vivid/excessive dreaming Symptoms are usually mild and self-limiting but in some cases may be severe and prolonged. Ensure patients are given adequate education on the symptoms they are likely to experience, onset and duration. General guidance- switching1 Cross-tapering is preferred when switch from one antidepressant to another: • Dose of current antidepressant is reduced slowly while slowly introducing the new antidepressant • Speed of cross-tapering should be based on individual patient tolerability • Not suitable for all situations (see table for further information) Risks associated with cross-tapering include: • Pharmacodynamic interactions o Serotonin syndrome o Hypotension o Drowsiness • Pharmacokintetic interactions o Increased plasma levels of tricyclics by some SSRIs • Antidepressant discontinuation symptoms o Could be mistakenly interpreted
    [Show full text]
  • Major Depressive Disorder
    ITEM 6.8a NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Vortioxetine for the treatment of major depressive disorder Draft scope (pre-referral) Draft remit/appraisal objective To appraise the clinical and cost effectiveness of vortioxetine within its licensed indication for the treatment of major depressive disorder. Background Major depressive disorder is a broad and heterogeneous condition associated with a range of cognitive, behavioural, emotional, and physical symptoms. Central to major depressive disorder is low mood and/or loss of pleasure in most activities. The severity of the disorder may vary from mild to severe depending on both the number of symptoms and the degree of functional impairment. In severe cases, psychotic symptoms such as hallucination or delusion may be present. Major depressive disorder often has a remitting and relapsing course, and symptoms may persist between episodes. In the UK, the prevalence of major depressive disorder ranges from 5% to 10% of people seen in primary care settings and 10% to 14% of medical inpatients. The risk of relapse is 50%, 70%, and 90% after the first, second, and third episodes of major depressive disorder respectively. The rate of major depressive disorder in women is two times the rate in men. In older adults, major depressive disorder is relatively rare although between 10% and 15% of older people have depressive symptoms. NICE clinical guideline 90 advocates a stepwise approach for the management of major depressive disorder. The routine use of antidepressants to treat mild major depressive disorder is not recommended except for those who have a past history of moderate or severe major depressive disorder or who have mild major depressive disorder that persists after other interventions.
    [Show full text]